Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.45 |
| ▸ | F11 | P03951 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29744209 | 1.00 | LPL (0.49) | LPLLIPGDGAT1F11FFAR1 | |
| SCHEMBL3803828 | 0.85 | DGAT1 (0.44) | LPLLIPGDGAT1F11FFAR1 | |
| SCHEMBL28769722 | 0.85 | DGAT1 (0.44) | LPLLIPGDGAT1F11FFAR1 | |
| SCHEMBL31469579 | 0.85 | LPL (0.45) | LPLLIPGDGAT1F11FFAR1 | |
| SCHEMBL2428561 | 0.85 | LPL (0.45) | LPLLIPGDGAT1F11FFAR1 | |
| SCHEMBL2316680 | 0.85 | DGAT1 (0.47) | LPLLIPGDGAT1F11FFAR1 | |
| SCHEMBL14873045 | 0.83 | DGAT1 (0.49) | LPLLIPGDGAT1F11FFAR1 | |
| SCHEMBL2486269 | 0.83 | DGAT1 (0.46) | LPLLIPGDGAT1F11FFAR1 | |
| SCHEMBL23816604 | 0.82 | DGAT1 (0.45) | LPLLIPGDGAT1F11FFAR1 | |
| SCHEMBL15941165 | 0.82 | DGAT1 (0.42) | LPLLIPGDGAT1F11FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12239630-B2 | Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-03-04 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-12023319-B2 | Carboxylic acid aromatic amides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-07-02 | — | — | US | disclosed |
| US-12023319-B2 | Carboxylic acid aromatic amides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-07-02 | — | — | US | disclosed |
| US-11999727-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-2366699-B1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| EP-2366699-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-09-21 | — | — | EP | disclosed |
| EP-2366699-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-09-21 | — | — | EP | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12023319-B2 | Carboxylic acid aromatic amides | DDC, PAH, NAT1 | LPL 4127/4885LIPG 2020/4885DGAT1 2103/4885 |
| US-11999727-B2 | Compounds and methods of use | F12, C1R, ABCG2 | LPL 2221/4885LIPG 2618/4885DGAT1 4031/4885 |
| US-12239630-B2 | Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor | BDKRB1, BDKRB2, HCAR1 | LPL 4356/4885LIPG 1582/4885DGAT1 3600/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | LPL 2221/4885LIPG 2618/4885DGAT1 4031/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | LPL 2221/4885LIPG 2618/4885DGAT1 4031/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | LPL 3942/4885LIPG 3515/4885DGAT1 2713/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | LPL 2221/4885LIPG 2618/4885DGAT1 4031/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | LPL 2221/4885LIPG 2618/4885DGAT1 4031/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | LPL 1131/4885LIPG 1319/4885DGAT1 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.